| Literature DB >> 34522638 |
Sumit K Arora1, Prashant R Verma2, Prakash R Itankar3, Satyendra K Prasad3, Kartik T Nakhate4.
Abstract
BACKGROUND AND AIM: Flavonoid rich plant Tephrosia purpurea (T. purpurea), commonly known as Sarpunkha has been used in traditional systems of medicine to treat diabetes mellitus. However, its effectiveness in promoting regeneration of pancreas in diabetes has not been investigated. Therefore, the present study was undertaken to evaluate pancreatic β-cells regeneration, antioxidant and antihyperlipidemic potentials of T. purpurea leaves extract, its fractions and main constituent Rutin in diabetic rats. EXPERIMENTAL PROCEDURE: The leaves extract and its fractions were first screened for acute and sub-chronic antidiabetic activity in a dose range of 250-500 mg/kg orally. Further, fractions with potent antidiabetic activity were screened for pancreatic β-cells regeneration activity using histopathological studies and morphometric analysis, which was followed by estimation of biochemical parameters. RESULTS ANDEntities:
Keywords: Antioxidant activity; Biochemical estimation; Diabetes mellitus; Pancreatic β-cell; Plant extracts; Polyphenol
Year: 2021 PMID: 34522638 PMCID: PMC8427475 DOI: 10.1016/j.jtcme.2021.03.001
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Total Polyphenol, Flavonoid, Flavanone, Total flavonoid, Rutin content, Degree of polymerization and Antioxidant potential of Tephrosia purpurea extract and its fractions.
| Sr. No. | Extract/Fractions | Total Polyphenol Content (TP) | Flavonoid Content (TFA) | Flavanone Content (TFO) | Total Flavonoid | Rutin content (% w/w of extract) | Degree of polymerization | Antioxidant activity (IC 50 values in μg/ml) |
|---|---|---|---|---|---|---|---|---|
| 1 | TPLE | 140.59 ± 0.036∗∗ | 24.07 ± 0.037∗∗ | 2.46 ± 0.021∗∗ | 26.53 | 22.88 ± 1.2802 | 5.84 | 1.65 23.94 |
| 2 | TPLCS | 20.5 ± 0.001 | 12.56 ± 0.020∗ | 0.713 ± 0.002∗ | 16.273 | Nil | 1.31 | 13.16 100.81 |
| 3 | TPLBS | 192.48 ± 0.017∗∗ | 28.857 ± 0.38∗∗ | 3.446 ± 0.005∗ | 33.303 | 33.458 ± 1.2486 | 6.67 | 1.26 18.19 |
| 4 | TPLBIS | 14.25 ± 0.023∗ | 10.92 ± 0.017 | 0.226 ± 0.0034 | 11.146 | 0.09 ± 0.0004 | 1.30 | 23.89 158.69 |
Results are represented as mean ± S.E.M. of three replicates: GAE, RE and NE: Gallic acid, Rutin and Naringin equivalents, respectively.
# Total flavonoid content is determined by adding flavonoid content with flavanone content.
TPLE, ethanolic extract of Tephrosia purpurea; TPLCS, Chloroform soluble fraction of TPLE; TPLBS, n-butanol soluble fraction of TPLE; TPLBIS, n-butanol insoluble fraction of TPLE.
∗Represents statistical significance (p < 0.05). ∗∗Represents statistical significance (p < 0.001).
Fig. 1Effect of acute treatment with T. purpurea leaves extract and its fractions on blood glucose levels in diabetic rats. Extract and its fractions were administered to diabetic rats and the blood samples were withdrawn at 1-, 3-, 5- and 24-h time-points for assessing antidiabetic potential. The bars values represent the mean ± S.E.M. The data were analyzed with one-way analysis of variance (ANOVA) followed by Dunnett post-hoc comparisons test. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. diabetic control. TPLE, ethanolic extract; TPLCS, chloroform soluble fraction of ethanolic extract; TPLBS, n-butane soluble fraction of ethanolic extract, TPLBIS, n-butane insoluble fraction of ethanolic extract.
Fig. 2Effect of sub-acute treatment with T. purpurea leaves extract and its fractions on blood glucose levels in diabetic rats. Extract and its fractions were administered to diabetic rats daily for 21 days and the blood samples were withdrawn on day 7, 14 and 21 for assessing antidiabetic potential. The bars values represent the mean ± S.E.M. The data were analyzed with one-way analysis of variance (ANOVA) followed by Dunnett post-hoc comparisons test. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001vs. diabetic control. TPLE, ethanolic extract; TPLCS, chloroform soluble fraction of ethanolic extract; TPLBS, n-butane soluble fraction of ethanolic extract.
Fig. 3Effect of T. purpurea leaves extract and its fractions on lipid parameters in diabetic rats. Extract and its fractions were administered to diabetic rats daily for 21 days and the blood samples were withdrawn on 21 for assessing lipid parameters. The bars values represent the mean ± SEM. The data were analyzed with one-way analysis of variance (ANOVA) followed by Dunnett post-hoc comparisons test. #P < 0.001 vs normal control; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. diabetic control. TPLE, ethanolic extract; TPLCS, chloroform soluble fraction of ethanolic extract; TPLBS, n-butane soluble fraction of ethanolic extract.
Effect of T. purpurea extract and its fractions on SOD, GSH, CAT and LPO in STZ-induced diabetic rats in pancreatic tissue and erythrocytes.
| Treatment | Pancreatic Tissue | Erythrocyte lysate | ||||||
|---|---|---|---|---|---|---|---|---|
| SOD (nM/g of tissue) | CAT (U/mg of protein) | GSH (nM/mg of protein) | LPO (nM/g of protein) | SOD (U/mg of protein) | CAT (U/mg of protein) | GSH (nM/mg of protein) | LPO (nM/g of protein) | |
| Normal Control | 67.58 ± 2.56 | 85.28 ± 3.25∗∗ | 52.31 ± 1.26 | 13.2 ± 1.1∗∗ | 6.32 ± 0.255 | 111 ± 2∗∗ | 15.024 ± 0.21 | 14.2 ± 0.356∗ |
| Diabetic Control | 40.65 ± 3.1∗ | 35.2 ± 2 .31∗ | 22.36 ± 0.99 | 70.25 ± 1.1 | 3.30 ± 0.28∗ | 52.5 ± 1.38 | 7.14 ± 0.44∗∗ | 28.59 ± 1.53∗ |
| Insulin (4 IU/kg, | 63.89 ± 1.65∗∗ | 79.56 ± 5.54 | 47.38 ± 2.4∗∗∗ | 15.25 ± 1.1∗∗∗ | 6.18 ± 0.04 | 106 ± 1.24 | 14.1 ± 1.01∗ | 13.0 ± 0.8∗∗∗ |
| Rutin (100 mg/kg, | 60.23 ± 3.78∗ | 79.2 ± 1.25∗ | 49.7 ± 1.87 ∗∗ | 17.5 ± 0.42∗∗∗ | 4.51 ± 0.02 | 87.85 ± 3.14∗ | 14 ± 1.6∗∗ | 16.6 ± 0.21∗∗∗ |
| TPLE (500 mg/kg, | 58.45 ± 4.1∗ | 74.2 ± 2.47 | 39 ± 1∗ | 40.91 ± 1.26∗ | 4.35 ± 0.27∗ | 87.45 ± 2.23∗ | 9.0 ± 1∗∗ | 20.37 ± 1.89 |
| TPLCS (500 mg/kg, | 60.26 ± 2.46∗∗ | 78.9 ± 2.35∗∗ | 45.29 ± 4.3 | 22.51 ± 1.45 | 5.9 ± 0.22 | 99.85 ± 2.4 | 12.1 ± 0.56 | 16.8 ± 0.45∗∗ |
| TPLBS (500 mg/kg, | 67.25 ± 3.78 | 81.2 ± 2.25∗ | 51.28 ± 1.45∗∗ | 13.89 ± 1.78∗ | 6.38 ± 0.61 | 110.65 ± 1.28∗ | 15 ± 0.23∗ | 14.01 ± 0.27 |
TPLE, methanolic extract; TPLCS, chloroform soluble fraction of methanolic extract; TPLBS, n-butane soluble fraction of ethanol extract.
The data are expressed in mean ± S.E.M.
∗ Represents statistical significance vs. diabetic control (p < 0.05).
∗∗ Represents statistical significance vs. Diabetic control (p < 0.01).
∗∗∗ Represents statistical significance vs. Diabetic control (p < 0.001).
# Represents statistical significance vs. Normal control (p < 0.01).
Fig. 4Light photomicrographs of pancreatic sections from different experimental groups. Haematoxylin and eosin stained histopathological sections of pancreas after 21 days treatment (A) Normal control: Native architecture of islet and pancreatic tissue (B) Diabetic control: Islet of Langerhans displaying degenerative and necrotic changes in diabetic control rats (C) Insulin group: Islet of Langerhans displaying degenerative changes and less β cell granulation compare to normal rats (D) Rutin group: Islet of langerhans displaying increase in size with degenerative changes comparing to normal control group (E) TPLE group: dumbbell shaped pancrease representing the replication of islet on treatments with TPLE (F) TPLCS group: Islet of langerhans displaying increase in size and very light degenerative changes comparing to diabetic control group (G) TPLBS group: Enlarged islet of langerhans with architecture of cells very near to normal control group rats. Figs. A-C are taken from our previous study. (Magnification × 200, scale bar = 4 μm) 1: newly formed islet. 2: Intralobular duct from which the islet sprouted. 3: Glandular Acinus. 4: Intralobular connective tissue septa. 5: Blood vessels 6: Connection between the duct and the islet.
Effect of T. purpurea leaves extract and its selected fractions on islet size and there distribution pattern in STZ-induced diabetic rats after treatment for 21 days.
| Islet size (μm2) | Treatment | |||||
|---|---|---|---|---|---|---|
| Distribution of islet as per size | ||||||
| Normal Control | Diabetic Control | Insulin (4 IU/kg | TPLE (500 mg/kg; | TPLCS (500 mg/kg; | TPLBS (500 mg/kg; p.o.) | |
| <50 | 5 ± 1.2 | 2.5 ± 0.12 | 2 ± 0.15 | 7.66 ± 0.58∗ | 17.2 ± 1.2∗∗∗ | 25 ± 1.2∗∗∗ |
| 51–100 | 4 ± 0.3 | 5 ± 0.136 | 4 ± 0.12 | 3 ± 0.24 | 3 ± 0 | 5 ± 0.57 |
| 100–150 | 1.5 ± 0 | 3 ± 0.21 | 2 ± 0.6 | 0.33 ± 0 | 2 ± 0.37 | 7 ± 0.82∗∗ |
| 150–200 | 1 ± 0.01 | 2 ± 0.08 | 0 | 1 ± 0 | 1 ± 0.1 | 0 |
| 200–250 | 0.5 ± 0.21 | 0.5 ± 0.001 | 2 ± 0.11 | 0 | 0 | 0 |
| Average no. of islet per sq. μm of pancreas (X 10−3) | 0.51 ± 0.016 | 0.28 ± 0.002 | 0.0868 ± 0.0021 | 0.106 ± 0.001 | 0.846 ± 0.035∗∗∗ | 0.97 ± 0.029∗∗∗ |
| Average size of islet (μm2 X 10−3) | 76.9 ± 1.29 | 116.78 ± 2.37# | 184.54 ± 8.98# | 56.69 ± 1.28 | 36.67 ± 1 | 47.79 ± 1.3 |
| Islet area per sq. μm of pancreas | 3.285 ± 0.24 | 2.4883 ± 0.186 | 1.6018 ± 0.012 | 0.499 ± 0.002 | 0.845 ± 0.08 | 1.256 ± 0.012 |
TPLE, ethanolic extract; TPLCS, chloroform soluble fraction of ethanolic extract; TPLBS, n-butanol soluble fraction of ethanol extract.
The data are expressed in mean ± S.E.M.
∗ Represents statistical significance vs. diabetic control (p < 0.05).
∗∗ Represents statistical significance vs. Diabetic control (p < 0.01).
∗∗∗ Represents statistical significance vs. Diabetic control (p < 0.001).
# Represents statistical significance vs. Normal control (p < 0.01).